ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- Human Genome
Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a
conference call to discuss recent developments in its oncology portfolio.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )
The conference call will be hosted by senior management and will be
held on Wednesday, April 16, 2008 at 5:00 pm Eastern Time.
Investors may listen to the call by dialing (800) 930-1344 or (913)
312- 1416, passcode 8678241, five to 10 minutes before the start of the
call. A replay of the conference call will be available for several days by
dialing (888) 203-1112 or (719) 457-0820, passcode 8678241.
This conference call also will be webcast and may be accessed at
http://www.hgsi.com . Investors interested in listening to the live webcast should
log on before the conference call begins in order to download any software
required. The archive of the conference call will remain available for
several days.
The mission of HGS is to apply great science and great medicine to
bring innovative drugs to patients with unmet medical needs.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences,
Inc.
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. The
forward-looking statements are based on Human Genome Sciences' current
intent, belief and expectations. These statements are not guarantees of
future performance and are subject to certain risks and uncertainties that
are difficult to predict. Actual results may differ materially from these
forward-looking statements because of the Company's unproven business
model, its dependence on new technologies, the uncertainty and timing of
clinical trials, the Company's ability to develop and commercialize
products, its dependence on collaborators for services and revenue, its
substantial indebtedness and lease obligations, its changing requirements
and costs associated with planned facilities and clinical trials, intense
competition, the uncertainty of patent and intellectual property
protection, the Company's dependence on key management and key suppliers,
the uncertainty of regulation of products, the impact of future alliances
or transactions and other risks described in the Company's filings with the
Securities and Exchange Commission. In addition, the Company will continue
to face risks related to animal and human testing, to the manufacture of
ABthrax and to FDA concurrence that ABthrax meets the requirements of the
ABthrax contract. If the Company is unable to meet the product requirements
associated with the ABthrax contract, the U.S. Government will not be
required to reimburse the Company for the costs incurred or to purchase any
ABthrax doses. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which speak only
as of today's date. Human Genome Sciences undertakes no obligation to
update or revise the information contained in this announcement whether as
a result of new information, future events or circumstances or otherwise.
SOURCE Human Genome Sciences, Inc.
 back to top
Related links:
http://www.hgsi.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO
AP Archive: http://photoarchive.ap.org PRN Photo Desk
photodesk@prnewswire.com
http://www.prnewswire.com/comp/121115.html /
CONTACT:
Jerry Parrott, Vice President, Corporate
Communications, +1-301-315-2777, or Kate de Santis, Director,
Investor Relations, +1-301-251-6003, both of Human Genome
Sciences, Inc.
|
